Hanmi Science Co., Ltd. (KRX:008930)
44,700
+2,100 (4.93%)
At close: Feb 4, 2026
Hanmi Science Revenue
Hanmi Science had revenue of 362.10B KRW in the quarter ending September 30, 2025, with 7.12% growth. This brings the company's revenue in the last twelve months to 1.34T, down -0.06% year-over-year. In the year 2024, Hanmi Science had annual revenue of 1.28T with 2.85% growth.
Revenue (ttm)
1.34T
Revenue Growth
-0.06%
P/S Ratio
2.25
Revenue / Employee
2.82B
Employees
476
Market Cap
3.03T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28T | 35.53B | 2.85% |
| Dec 31, 2023 | 1.25T | 201.85B | 19.30% |
| Dec 31, 2022 | 1.05T | 95.89B | 10.09% |
| Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
| Dec 31, 2020 | 857.38B | 40.76B | 4.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 3.90T |
| Hugel | 404.19B |
| ST Pharm | 318.32B |
| Celltrion Pharm | 274.73B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| Hanall Biopharma | 154.05B |